And the plot thickens for short course RT in rectal cancer! 72% cCR & 57% 2-year TME free survival via 4 cycles FOLFOX/CAPOX --> 25-30Gy/5 fraction RT (short course with optional boost). Congrats @adapthyun & looking forward to study details. #ASTRO25

Charles Yang Medley - LIVE from 33 West https://t.co/UB4iCPo29b via @YouTube Being 💯 focused on treating cancer & still seeing so many pts/family/humans suffer from it and inadequate rx can drive one near nihilism. And some days the algorithm says persevere. Thx Universe🤟

My favorite meeting of the year in the beautiful San Francisco #GI26. And when @MaryFengMD is in charge of the program… it’s sure to be stellar!! @ASCO

Panelists @marshalj23, @mgfakih, @adasarimd, and @DrKatePedersen review treatment options in third-line mCRC and therapy sequencing strategies. https://t.co/3QWmwcMlVk via @onclive

Are you an oncologist with interest in GI cancer? If so, are you interested in joining a growing academic GI Oncology practice in Rochester, MN? We have 13 GI oncs with additional 3 joining soon and still growing 😀 We are hiring! PM me if interested. https://t.co/Fd8lRVsBfM

It was an honor not only to speak at #BestofASCO @ASCO this morning, but especially to watch @realbowtiedoc in live Twitter action! 🤩🤩🤩 Pleasure seeing you, Joseph! #viewfromthepodium

Panelists @marshalj23, @mgfakih, @adasarimd, and @DrKatePedersen discuss the role of ctDNA in the Management of mCRC. https://t.co/4KpdfTuvUI via @onclive

Panelists @marshalj23, @mgfakih, @adasarimd, and @DrKatePedersen discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the

🧬Spoiler alert: it’s important. Really important. And becomes more so this past year. #breakwater #checkmate8hw How/when do you test? 🤔 Thanks @OncLive @marshalj23 for giving an excuse to chat and learn from each other 🙏

Want a quick update in medical oncology on July 19 (with some heme updates in the mix)...? If so, we have the course for you! I can promise excellent content/speakers and there is a livestream (virtual) option too for those who cannot attend in person. https://t.co/PHllzjlLUB

As another Annual Meeting winds down, I’m reminded of what the @ASCO acronym actually stands for: Academic Summer Camp for Oncologists Bet you didn’t know that 😂👍 Some fantastic data, heated debates, and thought provoking convos for GI cancers this #ASCO25 See you all soon

Yankee Hotel Foxtrot…was released 24(!) years ago and is still the only thing I think of whenever I’m by the Chicago River for some reason… 🤔😬 #ASCO25

CRC staging: AJCC v9 Era Past: “TNM.” Now: “TNDM” staging system, incorporating tumor deposits as independent entity. I like it. Better than N1c grouping-better reflects survival risk. Will be a learning curve though… AJCC v10 prediction: TNDM+ctDNA 🤔

Another year with a great ASCO plenary viewing group! Love your insights #richardwilson @MadisonConces @smitha42 @KristenCiombor #staceycohen @aparna1024 #christinawu

🥳 Adjuvant FOLFOX/Atezo vs FOLFOX for resected dMMR stage 3 colon cancer more positive than I expected—DFS 3 yr 0.50 ! My opinion of trial we need now: randomized neoadj ICI vs adj ICI +|- chemo vs periop ICI Excellent presentations @FASinicropeMD @MyriamChalabi 🤩

Come to this— @ParseghianC and I will make this year’s pivotal GI data interesting for you. And MSP in July is not to be missed. #BestofASCO25

Get key takeaways from the ASCO Annual Meeting in our 2-day high-impact, expert-led and curated learning experience, Best of ASCO Minneapolis. Register TODAY for our best rates. #ASCO25

BREAKWATER shows that 1L EC+FOLFOX results in mPFS 12.8m and mOS 30.3m!! 🥹🥲 That mOS far exceeded my greatest hope for this study. A great turning point for a bad actor 🙌👊🏻 #ASCO25

Getting excited for #ASCO25, especially to see *ATOMIC* data during Plenary session (LBA1)! Cautiously optimistic that this means our stage III dMMR patients will benefit 🙌 Congrats to @FASinicropeMD #Alliance 🥳 https://t.co/mLDxSqLPCp

We prefer fair and balanced clocks. Daylight Saving Time is a mandate to wake early and sleep less. Permanent Standard Time keeps the sun’s zenith at noon—best for health and safety!